This is a summary of the European public assessment report (EPAR) for Relistor. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Relistor. For practical information about using Relistor, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
Treatment of opioid\-induced constipation in advanced\-illness patients who are receiving palliative care when response to usual laxative therapy has not been sufficient.
Therapeutic Area (MeSH)
ATC Code
A06AH01
ATC Item
N/A
Pharmacotherapeutic Group
Peripheral opioid receptor antagonists
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| methylnaltrexone bromide | N/A | methylnaltrexone bromide |
EMA Name
Relistor
Medicine Name
Relistor
Aliases
N/ANo risk management plan link.
